- TWD5.20bn
- TWD7.69bn
- TWD8.92bn
- 63
- 66
- 28
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.69 | ||
| Price to Tang. Book | 0.69 | ||
| Price to Free Cashflow | 11.94 | ||
| Price to Sales | 0.58 | ||
| EV to EBITDA | 11.82 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.2% | ||
| Return on Equity | 4.25% | ||
| Operating Margin | 3.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 8,181.06 | 7,949 | 8,456.51 | 8,574.72 | 8,918.89 | n/a | n/a | 2.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +42.53 | -6.85 | -7.69 | -32.56 | +131.33 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cenra Inc is a Taiwan-based company mainly engaged in the provision of general investment related businesses. Through its subsidiary, the Company conducts the development, manufacturing and sales of pharmaceuticals, agricultural and livestock drugs, personal hygiene and health products and the import and sale of medical instruments. Its subsidiaries’ products are pharmaceuticals and health products, including human medicines, such as prescription and indicated drugs, over-the-counter medicines, and disease treatment products; medical equipment, such as blood pressure monitors, blood glucose meters, and artificial joints; animal medicines, supplementary feeds, and feed additives, providing animal treatment, disease prevention, and nutritional supplement products; daily necessities, such as toothpaste, tooth powder, mouthwash and other oral hygiene and health products, hand cleansers, dry hand sanitizers, shower gels, medicated soaps and other lotion products, skin care series and other.
Directors
- Yi-Zhen Wang Xie CHM
- Chih-Yung Wu CTO
- Yin-Nan Sun DGM
- Chun-Ju Hsieh DGM
- Kuo-Chang Tsai DGM
- Yijun Huang OTH
- Hou-Jie Wang DRC
- Hung-Shou Chen IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 2nd, 2024
- Public Since
- September 2nd, 2024
- No. of Employees
- 1,401
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Taiwan Stock Exchange- Shares in Issue
- 148,514,000
- Address
- 2F, No.23, Hsiang Yang Road, Jhongjheng, TAIPEI, 100
- Web
- https://www.cenra.com/
- Phone
- +886 223124200
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 3716
Similar to 3716
Adimmune
Taiwan Stock Exchange
Bora Pharmaceuticals Co
Taiwan Stock Exchange
BRIM Biotechnology
Taiwan Stock Exchange
Caliway Biopharmaceuticals Co
Taiwan Stock Exchange
Chunghwa Chemical Synthesis & Biotech Co
Taiwan Stock Exchange
FAQ
As of Today at 19:50 UTC, shares in Cenra are trading at TWD35.00. This share price information is delayed by 15 minutes.
Shares in Cenra last closed at TWD35.00 and the price had moved by -20.81% over the past 365 days. In terms of relative price strength the Cenra share price has underperformed the FTSE Developed Asia Pacific Index by -19.91% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Cenra dividend yield is 2.86% based on the trailing twelve month period.
Last year, Cenra paid a total dividend of TWD1.00, and it currently has a trailing dividend yield of 2.86%. We do not have any data on when Cenra is to next pay dividends.
We do not have data on when Cenra is to next pay dividends. The historic dividend yield on Cenra shares is currently 2.86%.
To buy shares in Cenra you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD35.00, shares in Cenra had a market capitalisation of TWD5.20bn.
Here are the trading details for Cenra:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 3716
Based on an overall assessment of its quality, value and momentum Cenra is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cenra. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -2.53%.
As of the last closing price of TWD35.00, shares in Cenra were trading -10.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cenra PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD35.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cenra's management team is headed by:
- Yi-Zhen Wang Xie - CHM
- Chih-Yung Wu - CTO
- Yin-Nan Sun - DGM
- Chun-Ju Hsieh - DGM
- Kuo-Chang Tsai - DGM
- Yijun Huang - OTH
- Hou-Jie Wang - DRC
- Hung-Shou Chen - IND